Literature DB >> 22634613

Cathelicidin-related antimicrobial peptide is required for effective lung mucosal immunity in Gram-negative bacterial pneumonia.

Melissa A Kovach1, Megan N Ballinger, Michael W Newstead, Xianying Zeng, Urvashi Bhan, Fu-shin Yu, Bethany B Moore, Richard L Gallo, Theodore J Standiford.   

Abstract

Cathelicidins are a family of endogenous antimicrobial peptides that exert diverse immune functions, including both direct bacterial killing and immunomodulatory effects. In this study, we examined the contribution of the murine cathelicidin, cathelicidin-related antimicrobial peptide (CRAMP), to innate mucosal immunity in a mouse model of Gram-negative pneumonia. CRAMP expression is induced in the lung in response to infection with Klebsiella pneumoniae. Mice deficient in the gene encoding CRAMP (Cnlp(-/-)) demonstrate impaired lung bacterial clearance, increased bacterial dissemination, and reduced survival in response to intratracheal K. pneumoniae administration. Neutrophil influx into the alveolar space during K. pneumoniae infection was delayed early but increased by 48 h in CRAMP-deficient mice, which was associated with enhanced expression of inflammatory cytokines and increased lung injury. Bone marrow chimera experiments indicated that CRAMP derived from bone marrow cells rather than structural cells was responsible for antimicrobial effects in the lung. Additionally, CRAMP exerted bactericidal activity against K. pneumoniae in vitro. Similar defects in lung bacterial clearance and delayed early neutrophil influx were observed in CRAMP-deficient mice infected with Pseudomonas aeruginosa, although this did not result in increased bacterial dissemination, increased lung injury, or changes in lethality. Taken together, our findings demonstrate that CRAMP is an important contributor to effective host mucosal immunity in the lung in response to Gram-negative bacterial pneumonia.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22634613      PMCID: PMC3566644          DOI: 10.4049/jimmunol.1103196

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  40 in total

Review 1.  Ventilator-associated pneumonia: current status and future recommendations.

Authors:  Shai Efrati; Israel Deutsch; Massimo Antonelli; Peter M Hockey; Ronen Rozenblum; Gabriel M Gurman
Journal:  J Clin Monit Comput       Date:  2010-03-17       Impact factor: 2.502

Review 2.  Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.

Authors:  Ronald N Jones
Journal:  Clin Infect Dis       Date:  2010-08-01       Impact factor: 9.079

3.  Human endogenous antibiotic LL-37 stimulates airway epithelial cell proliferation and wound closure.

Authors:  Renat Shaykhiev; Christoph Beisswenger; Kerstin Kändler; Judith Senske; Annette Püchner; Thomas Damm; Jürgen Behr; Robert Bals
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2005-06-17       Impact factor: 5.464

Review 4.  Ventilator-associated pneumonia: Improving outcomes through guideline implementation.

Authors:  Tasnim Sinuff; John Muscedere; Deborah Cook; Peter Dodek; Daren Heyland
Journal:  J Crit Care       Date:  2008-03       Impact factor: 3.425

Review 5.  Cathelicidins: a family of endogenous antimicrobial peptides.

Authors:  Robert I Lehrer; Tomas Ganz
Journal:  Curr Opin Hematol       Date:  2002-01       Impact factor: 3.284

6.  Alveolar epithelial cell inhibition of fibroblast proliferation is regulated by MCP-1/CCR2 and mediated by PGE2.

Authors:  Bethany B Moore; Marc Peters-Golden; Paul J Christensen; Vibha Lama; William A Kuziel; Robert Paine; Galen B Toews
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2002-10-04       Impact factor: 5.464

7.  The antimicrobial peptide cathelicidin interacts with airway mucus.

Authors:  Kerstin Felgentreff; Christoph Beisswenger; Matthias Griese; Tanja Gulder; Gerhard Bringmann; Robert Bals
Journal:  Peptides       Date:  2006-09-11       Impact factor: 3.750

8.  Cathelicidin LL-37 increases lung epithelial cell stiffness, decreases transepithelial permeability, and prevents epithelial invasion by Pseudomonas aeruginosa.

Authors:  Fitzroy J Byfield; Marek Kowalski; Katrina Cruz; Katarzyna Leszczyńska; Andrzej Namiot; Paul B Savage; Robert Bucki; Paul A Janmey
Journal:  J Immunol       Date:  2011-11-16       Impact factor: 5.422

9.  Activity of antimicrobial peptides in the presence of polysaccharides produced by pulmonary pathogens.

Authors:  M Benincasa; M Mattiuzzo; Y Herasimenka; P Cescutti; R Rizzo; R Gennaro
Journal:  J Pept Sci       Date:  2009-09       Impact factor: 1.905

Review 10.  Immunomodulatory properties of defensins and cathelicidins.

Authors:  D M E Bowdish; D J Davidson; R E W Hancock
Journal:  Curr Top Microbiol Immunol       Date:  2006       Impact factor: 4.291

View more
  52 in total

1.  2-O-Sulfated Domains in Syndecan-1 Heparan Sulfate Inhibit Neutrophil Cathelicidin and Promote Staphylococcus aureus Corneal Infection.

Authors:  Atsuko Hayashida; Shiro Amano; Richard L Gallo; Robert J Linhardt; Jian Liu; Pyong Woo Park
Journal:  J Biol Chem       Date:  2015-04-30       Impact factor: 5.157

Review 2.  Dynamics of lung defense in pneumonia: resistance, resilience, and remodeling.

Authors:  Lee J Quinton; Joseph P Mizgerd
Journal:  Annu Rev Physiol       Date:  2014-08-13       Impact factor: 19.318

3.  The Mla pathway is critical for Pseudomonas aeruginosa resistance to outer membrane permeabilization and host innate immune clearance.

Authors:  Jason Munguia; Doris L LaRock; Hannah Tsunemoto; Joshua Olson; Ingrid Cornax; Joseph Pogliano; Victor Nizet
Journal:  J Mol Med (Berl)       Date:  2017-08-26       Impact factor: 4.599

Review 4.  Antimicrobial host defence peptides: functions and clinical potential.

Authors:  Neeloffer Mookherjee; Marilyn A Anderson; Henk P Haagsman; Donald J Davidson
Journal:  Nat Rev Drug Discov       Date:  2020-02-27       Impact factor: 84.694

5.  Anti-fungal activity of Ctn[15-34], the C-terminal peptide fragment of crotalicidin, a rattlesnake venom gland cathelicidin.

Authors:  Carolina Sidrim P Cavalcante; Cláudio B Falcão; Raquel Os Fontenelle; David Andreu; Gandhi Rádis-Baptista
Journal:  J Antibiot (Tokyo)       Date:  2016-11-23       Impact factor: 2.649

6.  Group A Streptococcal M1 Protein Sequesters Cathelicidin to Evade Innate Immune Killing.

Authors:  Christopher N LaRock; Simon Döhrmann; Jordan Todd; Ross Corriden; Joshua Olson; Timo Johannssen; Bernd Lepenies; Richard L Gallo; Partho Ghosh; Victor Nizet
Journal:  Cell Host Microbe       Date:  2015-10-14       Impact factor: 21.023

7.  Profiling of Polar Metabolites in Mouse Feces Using Four Analytical Platforms to Study the Effects Of Cathelicidin-Related Antimicrobial Peptide in Alcoholic Liver Disease.

Authors:  Liqing He; Fengyuan Li; Xinmin Yin; Patrick Bohman; Seongho Kim; Craig J McClain; Wenke Feng; Xiang Zhang
Journal:  J Proteome Res       Date:  2019-06-12       Impact factor: 4.466

8.  Antimicrobial and biophysical properties of surfactant supplemented with an antimicrobial peptide for treatment of bacterial pneumonia.

Authors:  Brandon J H Banaschewski; Edwin J A Veldhuizen; Eleonora Keating; Henk P Haagsman; Yi Y Zuo; Cory M Yamashita; Ruud A W Veldhuizen
Journal:  Antimicrob Agents Chemother       Date:  2015-03-09       Impact factor: 5.191

9.  Role of the cathelicidin-related antimicrobial peptide in inflammation and mortality in a mouse model of bacterial meningitis.

Authors:  Julika Merres; Jonas Höss; Lea-Jessica Albrecht; Eugenia Kress; Oliver Soehnlein; Sandra Jansen; Thomas Pufe; Simone C Tauber; Lars-Ove Brandenburg
Journal:  J Innate Immun       Date:  2013-08-22       Impact factor: 7.349

Review 10.  Bacterial Evasion of Host Antimicrobial Peptide Defenses.

Authors:  Jason N Cole; Victor Nizet
Journal:  Microbiol Spectr       Date:  2016-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.